We are an entrepreneurial and multi-disciplinary team of digital health experts, behavioral designers, clinical researchers, software engineers, and data scientists with a track record of successful co-development partnerships with pharmas and startups. Putting patient needs at the core of all our products, our methodology defines DTx and Digital Medicines products through a rigorous scientific analysis, commercial sustainability potential and strategic market fit. All of our solutions are created exclusively in-house by our technical team, and proof of concepts and MVPs development is accelerated thanks to our proprietary DTx platform (H.Core). Our capabilities and innovation offerings are augmented by an evolving “partner-ready” DTx solutions pipeline with some of our products having already reached full clinical validation. We also maintain an evergreen Digital Healthinnovation offering, seeking out novel solutions in all therapeutic areas via our Healthware Ventures arm, and by investing in the acceleration of promising new startups.
In a webinar held on 16 May, Petteri Kolehmainen, senior member of Healthware Group, discussed trends and solutions offered to various companies in the difficult task of recruiting patients for clinical trials
It was the first time back in person at SXSW post pandemic, and things were a bit more subdued than in years past, but the energy and optimism for the future was palpable.